Tibet Pharmaceutical (600211): Sales of neovactin are growing rapidly
Tibet Pharmaceutical (600211): New actin production capacity is about to be released, negative effects will be released, and a light package will be launched
Tibet Pharmaceutical (600211): Performance is in line with expectations, and I am optimistic that the release of new active substances will accelerate
Tibet Pharmaceutical (600211): The quarterly report forecast exceeded expectations, and there is huge room for growth of new activities
Tibet Pharmaceutical (600211): Performance continues to grow at a high rate, and the growth rate of Xinxin in 2023 is expected to exceed 40%
Tibet Pharmaceutical Industry (600211): Leading Biopharmaceutical for Heart Failure with Undervalued Rapid Release of New Active Drugs
Tibet Pharmaceutical (600211): New active drug sales are impressive, revenue side growth is strong in 2021
Tibet Pharmaceutical (600211): Steady growth in the third quarter, new active substances are expected to continue to be released
Tibet Pharmaceutical Industry (600211): the performance is in line with expectations and the new active element is expected to continue to release.
Tibet Pharmaceutical (600211): Cooperation with Sri Lankan microorganisms focuses on COVID-19 vaccine research and development
Tibet Pharmaceutical (600211): Performance maintained steady growth and laid out in the field of cardiovascular implant devices
Comments on Tibetan Pharmaceutical Industry (600211) three Quarterly report in 2019: the performance is basically in line with the expected rapid growth of Xinhuo.
Tibet Pharmaceutical Industry (600211) in-depth report: after Xinhuo entered health insurance, its sustained high growth exceeded expectations and ushered in a significant performance inflection point in 2019.
Comments on Tibet Pharmaceutical Industry (600211) 2019: the rapid release of Xinhuo is expected to increase rapidly throughout the year.
Tibet Pharmaceutical (600211) 2019 Quarterly Report Review: Continued Release of New Active Subtracts and Non-High Growth Exceeds Expectations
Tibet Pharmaceutical Industry (600211) 2018 Annual report comments: short-term performance affected by impairment is expected to continue to release new activin
Comments on the quarterly report of Tibet Pharmaceutical Industry (600211): the performance exceeded expectations and continued release of new active elements.
西藏药业(600211)中报点评:新活素持续放量 未来发展空间可期
西藏药业(600211)季报点评:业绩保持稳定增长 新活素放量值得期待
西藏药业(600211)年报点评:新活素放量可期 依姆多增长稳健
No Data